L. D'Onofrio

[Systemic therapy for advanced triple-negative breast cancer in older women: strategy optimization and effectiveness of sacituzumab govitecan.]

Triple-negative breast cancer (TNBC) represents a major challenge for clinical oncologists, due to lack of therapeutical targets deriving from hormone-receptors and/or HER2 receptor expression. Moreover, TNBC typically shows a more aggressive clinical behavior and less responsiveness to traditional chemotherapy. Last y...